NCT02971670View on ClinicalTrials.gov

Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

May 31, 2016

Conditions
Toxic-Shock SyndromeSepsis
Interventions
BIOLOGICAL

rTSST-1 Variant Candidate Vaccine

Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Biomedizinische Forschungs gmbH

INDUSTRY

NCT02971670 - Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial | Biotech Hunter | Biotech Hunter